VivoSeq
Infectious Disease

Coronavirus Disease 2019

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Coronavirus Disease 2019 is an early-stage landscape with 0 programs across 2 companies. The most active players are Pfizer, EyePoint Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 1E

EyePoint Pharmaceuticals, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed6 · 67%
Unknown status1 · 11%
Terminated1 · 11%
Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 4-PERIOD, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY AND EFFECT OF FOOD FOLLOWING ORAL ADMINISTRATION OF A NEW TABLET FORMULATION RELATIVE TO THE ORIGINAL FORMULATION OF IBUZATRELVIR IN HEALTHY ADULT PARTICIPANTS
Active, not recruiting·Pfizer logoPfizer·Phase 1·NCT07552779·17 enrolled
Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients
Completed·MMateria Medica Holding·Phase 3·NCT05364671·771 enrolled
Adverse Events Related to Treatments Used Against Coronavirus Disease 2019
Completed·GGroupe Hospitalier Pitie-Salpetriere·N/A·NCT04314817·1,000 enrolled
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
Completed·SShanghai Children's Medical Center·N/A·NCT05501288·108 enrolled
C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.
Completed·MManimarane Arjunan, MD,DM (Cardiology)·N/A·NCT04935515·25 enrolled
Effect of Pentoxifylline on Prognosis of Coronavirus Disease 2019 (COVID- 19) Infection
Completed·—·N/A·NCT04739345·69 enrolled
Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019
Completed·—·Phase 1/2·NCT04883528·42 enrolled
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
Terminated·EEyePoint Pharmaceuticals, Inc.·Phase 2·NCT04511650·31 enrolled
Norwegian Coronavirus Disease 2019 Study
Unknown status·UUniversity Hospital, Akershus·Phase 4·NCT04316377·53 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)